TL;DR
This study identifies novel single-nucleotide variants (SNVs) in the 3' untranslated regions (3'UTRs) of genes that are implicated in congenital heart disease (CHD). These SNVs disrupt the regulatory function of microRNAs (miRNAs) on their target genes, offering a new perspective on the molecular mechanisms underlying CHD and potential avenues for diagnosis and therapy.
What Problem Does This Paper Address?
Congenital heart defects (CHDs) are the most common birth defects, with complex etiologies involving both genetic and environmental factors. While genetic mutations are known contributors, the precise molecular mechanisms are not fully understood for many cases. Previous research from the authors' lab suggested that malfunctioning microRNAs (miRNAs) in cardiac neural crest cells (NCCs) – crucial for heart development – play a role in CHD pathogenesis. However, the specific genetic variations that lead to these miRNA malfunctions in human CHD patients remained largely unknown. This paper aims to bridge that gap by identifying causative single-nucleotide variants (SNVs) within the 3'UTR regions of genes that can disrupt miRNA-mediated gene regulation in the context of CHD.
Methods
The researchers employed a multi-pronged approach:
- Paired-End Sequencing: They performed paired-end sequencing on DNA from a cohort of CHD patients and healthy controls. Probes were designed to capture key genomic regions, including the 3'UTR of selected genes known to be important for cardiac development.
- Variant Annotation: The identified SNVs were annotated using ANNOVAR to determine their location within genes and transcripts.
- miRNA Binding Site Identification: They utilized the miRDB database to predict miRNA-transcript pairs and then identified candidate miRNA binding sites within the 3'UTR sequences based on established complementarity rules.
- miRNA Profiling: To understand the miRNA landscape in relevant cells, they profiled miRNA expression in cardiac neural crest cells (NCCs) derived from mouse embryos using microarrays. This involved genetically engineering mice (Wnt1-Cre; Rosa-mTmG) to label and isolate GFP-positive NCCs.
- Integrated Analysis: They combined the SNV data with the miRNA expression profiles to identify SNVs located within predicted miRNA binding sites and expressed in cardiac NCCs.
- Experimental Validation: Promising SNVs were further validated using luciferase reporter assays. Wild-type and mutant 3'UTR fragments containing the identified SNVs were cloned into luciferase reporter constructs. These were then co-transfected with predicted miRNA mimics to assess the impact of the SNVs on miRNA-mediated gene repression.
- Sanger Sequencing: Selected SNVs were confirmed using Sanger sequencing.
Datasets
- CHD Patient Cohort: Data from 412 CHD patients and 213 healthy controls, collected between August 2008 and February 2011.
- Genomic DNA: Collected from the CHD patients and controls.
- miRNA Expression Data: Generated from cardiac NCCs and non-NCCs isolated from mouse embryos.
- miRDB Database: Used for predicting miRNA-transcript interactions.
- miRBase Database: Used for obtaining miRNA sequences.
- GENCODE GRCh37 Reference Genome: Used for transcript sequences.
- Gene Expression Omnibus (GEO) Database: Raw genome-wide data from this study was deposited under accession number GSE178823.
Key Insights and Ideas
- 3'UTR SNVs as a Novel Etiology for CHD: The study strongly suggests that SNVs in the 3'UTR of genes, which are often overlooked compared to coding region mutations, can be significant contributors to CHD by disrupting miRNA regulation.
- Cardiac NCCs as a Critical Cell Type: The focus on cardiac neural crest cells highlights their pivotal role in heart development and underscores how disruptions in these cells can lead to severe cardiac malformations.
- miRNA Dysregulation as a Mechanistic Link: The research provides a concrete molecular mechanism by which genetic variations (SNVs) can lead to disease – by interfering with the fine-tuning of gene expression by miRNAs.
- Specific SNVs Identified: The identification of three specific SNVs (NFATC1 c.654C>T, FGFRL1 c.414C>T, and CTNNB1 c.729_730insT) that experimentally disrupt miRNA-mediated gene regulation provides strong evidence for their role in CHD.
- Conotruncal and Septal Defects Link: The observation that all identified rare SNVs were associated with conotruncal or septal defects is a significant finding, suggesting these SNVs are likely causative for these specific types of CHD.
Key Results
- 2,925 3'UTR SNVs Detected: A total of 2,925 SNVs were identified in the 3'UTR regions of selected genes from the CHD cohort.
- 201 Expressed miRNAs in Cardiac NCCs: The study profiled and identified 201 expressed miRNAs in cardiac NCCs.
- Three Novel SNVs Identified and Validated: Three specific 3'UTR SNVs (NFATC1 c.654C>T, FGFRL1 c.414C>T, and CTNNB1 c.729_730insT) were identified as potentially mediating miRNA malfunction and were experimentally validated to disrupt miRNA-mediated gene regulation.
- SMAD2 SNV Prediction Not Validated: While a fourth SNV in SMAD2 was predicted to be involved, its interaction with miR-145-5p was not experimentally validated to show repression.
- Experimental Validation Success: Luciferase assays confirmed that miR-143-3p, miR-210-3p, and miR-214-3p inhibited the activity of wild-type reporters, and this inhibition was diminished or abolished in the presence of the respective SNVs.
Limitations and Future Work
- Limited Gene Set: The study focused on a pre-selected set of ~250 genes important for cardiac development, rather than whole-genome sequencing. This means other potential SNVs in non-selected genes might have been missed.
- Mouse Model vs. Human: While mouse NCCs were used for miRNA profiling, the SNVs were identified in human patients. Further validation in human cell models or genetically engineered mouse models with the specific human SNVs would strengthen the findings.
- In Vivo Validation: The experimental validation was performed in vitro using luciferase assays. The authors suggest that introducing these identified mutations into mouse models would be crucial for further confirming their role in vivo.
- Broader Investigation: The authors propose investigating mutations in miRNA coding sequences and regulatory regions of miRNA primary transcripts as future directions. They also advocate for whole-genome sequencing to identify a more comprehensive set of SNVs.
- Clinical Application: The study opens doors for future research into the diagnostic and therapeutic potential of targeting miRNA-mediated gene dysregulation in CHD.
Summary updated